Anti-Golimumab (Simponi®)

ImmunoGuide® Enzyme immunoassay (ELISA) test kit for the determination of free antibodies directed against the drug Golimumab (Simponi®) in serum and plasma.<br><br>

The drug Golimumab (trade name Simponi®) is a human monoclonal antibody that binds to both the soluble and transmembrane bioactive forms of human TNF-α. This interaction prevents the binding of TNF-α to its receptors, thereby inhibiting the biological activity of TNF.<br><br>

Golimumab has been proven effective in the treatment of Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) or Ulcerative Colitis (UC). Antibodies to Golimumab were detected in 57 (4%) of Golimumab -treated patients across the Phase 3 RA, PsA, and AS trials through Week 24. The data from the literature demonstrated that Anti-Drug Antibody positivity was significantly associated with low Golimumab levels and poor therapeutic response. The positive correlation between serum drug trough levels and therapeutic response indicates that drug monitoring could be useful for optimising the dosing of biologics in a personalised therapy strategy.<br><br>

The ImmunoGuide Antibody to Golimumab ELISA Kit can be efficiently used for monitoring Anti-Golimumab antibodies during therapy and offers the clinician a tool for decision on possible preventive measures to reduce Anti-Golimumab antibodies. For research use only, not for use in diagnostic procedures.